Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Fullmektig i EP:
2018.11.14, CN 201811351660
Baozhu Zeng et al. Life Sciences 282 (2021) 119811 (B1)
XIAOFENG WEN ET AL: "Epigenetics, microbiota, and intraocular inflammation: New paradigms of immune regulation in the eye", PROGRESS IN RETINAL AND EYE RESEARCH, vol. 64, 19 January 2018 (2018-01-19), pages 84 - 95, XP055707633 (B1)
CN-A- 103 805 678 (B1)
GUEDEZ LILIANA ET AL: "Antibiotic Treatment Exacerbates Focal Retinal Degeneration in a Mouse Model of AMD", vol. 56, 2015, pages 276, XP055868840, Retrieved from the Internet <URL:https://iovs.arvojournals.org/article.aspx?articleid=2332559> [retrieved on 20211203] (B1)
Gouras, Peter, et al. Graefe's archive for clinical and experimental ophthalmology 246 (2008): 1395-1402 (B1)
Gouras, Peter, et al. Graefe's archive for clinical and experimental ophthalmology 246 (2008): 1403-1411 (B1)
HOSAKA S ET AL: "In vivo evaluation of ocular inserts of hydrogel impregnated with antibiotics fop trachoma therapy", BIOMATERIALS, vol. 4, no. 4, 1983, pages 243 - 248, XP022835621 (B1)
Ishibashi, Tatsuro, et al. Investigative ophthalmology & visual science 27.2 (1986): 184-193 (B1)
KALAYOGLU M V ET AL: "Serological association between Chlamydia pneumoniae infection and age-related macular degeneration", ARCHIVES OF OPHTHALMOLOGY, vol. 121, no. 4, 2003, pages 478 - 482, XP003024595 (B1)
MURAT V. KALAYOGLU ET AL.: "Serological Association Between Chlamydia pneumoniae Infection and Age-Related Macular Degeneration", CHINESE LANGUAGE EDITION OF ARCHIVES OF OPHTHALMOLOGY, vol. 16, no. 3, 25 July 2007 (2007-07-25), XP003024595, ISSN: 1000-9426 (B1)
Olin, Katherine L., et al. Proceedings of the Society for Experimental Biology and Medicine 208.4 (1995): 370-377 (B1)
Pennesi, et al. Molecular Aspects of Medicine 33.4 (2012): 487-509 (B1)
Picaud et al. PNAS, December 26, 2019, vol. 116 , no. 52, 26280-26287 (B1)
R.J. Ulshafer et al. Retina, Volume 7, Number 3, 198-203 (B1)
Shinsuke Umeda et al. The FASEB Journal express article 10.1096/fj.04-3525fje, Published online August 12, 2005 (B1)
US-A1- 2014 162 308 (B1)
US-A1- 2018 272 009 (B1)
WO-A1-2018/058078 (B1)
WO-A1-2018/119439 (B1)
CN-A- 101 880 705 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3877004)
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3877004)
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 7. avg. år (EP) expand_more expand_less | 2025.03.31 | 2860,0 | 1/ACUMASS | Betalt og godkjent |
Årsavgift 7. avg. år (EP)
2860,0 = 1 X 2860,0
En ordre på saken er opprettet av: OLIVIER BARLOY (20.03.2025 14:42:56): Betalt |
||||
Årsavgift 6. avg. år (EP) | 2024.04.25 | 2600 | CPA GLOBAL LIMITED | Betalt og godkjent |
32400976 expand_more expand_less | 2024.01.25 | 5500 | Murgitroyd & Company | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|